A phase II study to determine relapse-free interval after withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission

DOI number 10.58109/0xqy-d239
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

David Ross (Institute of Medical and Veterinary Science)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 40 patients with newly diagnosed CML
  • Trial followed CML patients, post TKI thereapy, in complete remission. Patients were monitored for disease relapse post initial treatment.
  • Dataset includes demographic data, diagnostic, treatment data, outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

ANZCTR Reference ACTRN12606000118505
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au